Lilly’s Olumiant Cuts COVID-19 Hospital Stays By One Day

Company Will Seek An EUA For Baricitinib Plus Remdesivir

 
• By Mandy Jackson

Olumiant (baricitinib) plus Gilead’s Veklury (remdesivir) provided a statistically significant reduction in time to recovery versus remdesivir alone for hospitalized patients in US NIAID’s ACTT-2 clinical trial. 

coronavirus covid 19 infected patient in quarantine room with quarantine and outbreak alert sign at hospital with coronavirus covid 19 disease control experts make coronavirus disease treatment
Olumiant/Veklury bested Veklury alone in hospitalized COVID-19 patients • Source: Shutterstock

More from COVID-19

More from Scrip